Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.73 |
| ▸ | HRH1 | P35367 | 2/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | DRD1 | P21728 | 1/20 | 0.73 |
| ▸ | ACHE | P22303 | 1/20 | 0.73 |
| ▸ | HRH2 | P25021 | 1/20 | 0.73 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780358 | 1.00 | SLC6A4 (0.78) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Diethylamine SCHEMBL17984038 | 0.94 | SLC6A4 (0.69) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL17983975 | 0.92 | SLC6A4 (0.67) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL141623 | 0.92 | SLC6A4 (0.83) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2865623 | 0.87 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL13234952 | 0.87 | SLC6A4 (0.84) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL6923491 | 0.87 | SLC6A4 (0.84) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2857332 | 0.87 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL2868968 | 0.87 | SLC6A4 (0.76) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| SCHEMBL4169876 | 0.87 | SLC6A4 (0.76) | SLC6A4SLC6A2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3309142-A1 | METHOD FOR PREPARING CITALOPRAM GLYCOL INTERMEDIATE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-04-18 | — | — | EP | disclosed |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-04-19 | — | — | US | disclosed |
| US-20110065938-A1 | METHOD FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2011-03-17 | — | — | US | disclosed |
| EP-1522539-B1 | Crystalline composition containing escitalopram | LUNDBECK & CO AS H (DK) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006021971-A2 | 'PROCESS FOR PREPARATION OF CITALOPRAM AND ENANTIOMERS' | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065938-A1 | METHOD FOR THE PREPARATION OF ESCITALOPRAM | GSK3B, GSK3A, SLC6A4 | SLC6A4 3/4885SLC6A2 9/4885HTR2C 20/4885 |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | FLI1, CDC73, FOS | SLC6A4 916/4885SLC6A2 957/4885HTR2C 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.